Key result
Triple-therapy was associated with better median cancer-specific survival (49 vs 34 months) and overall survival (49 vs 35 months) compared to surgery plus chemotherapy in DSRCT patients.
Why the study?
Desmoplastic small round cell tumor is a rare undifferentiated malignant soft tissue tumor with poor prognosis and lacking treatment consensus.
Does triple-therapy improve survival compared to surgery plus chemotherapy in patients with desmoplastic small round cell tumor?
Cohort (n=374)
Yes
Does triple-therapy improve survival compared to surgery plus chemotherapy in patients with desmoplastic small round cell tumor?
Answers are grounded in this paper and cite their sources.
A nomogram based on SEER data accurately predicts survival in DSRCT patients, and propensity score matching suggests triple-therapy (surgery, chemotherapy, radiation) improves survival compared to surgery plus chemotherapy.
Desmoplastic small round cell tumor (DSRCT) is a rare undifferentiated malignant soft tissue tumor with a poor prognosis and a lack of consensus on treatment. This study’s objective was to build a nomogram based on clinicopathologic factors and an online survival risk calculator to predict patient prognosis and support therapeutic decision-making. A retrospective cohort analysis of the Surveillance, Epidemiology and End Results (SEER) database was performed for patients diagnosed with DSRCT between 2000 and 2019. The least absolute shrinkage and selection operator (LASSO) Cox regression analysis was applied to identify the individual variables related to overall survival (OS) and cancer-specific survival (CSS), as well as to construct online survival risk calculators and nomogram survival models. The nomogram was employed to categorize patients into different risk groups, and the Kaplan-Meier method was utilized to determine the survival rate of each risk category. Propensity score matching (PSM) was used to assess survival with different therapeutic approaches. A total of 374 patients were included, and the median OS and CSS were 25 (interquartile range 21.9-28.1) months and 27 (interquartile range 23.6-30.3) months, respectively. The nomogram models demonstrated high predictive accuracy. PSM found that patients with triple-therapy had better CSS and OS than those who received surgery plus chemotherapy (median survival times: 49 vs 34 months and 49 vs 35 months, respectively). The nomogram successfully predicted the DSRCT patients survival rate. This approach could assist doctors in evaluating prognoses, identifying high-risk populations, and implementing personalized therapy.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2023) conducted a cohort in Desmoplastic small round cell tumor (n=374). Triple-therapy vs. Surgery plus chemotherapy was evaluated on Cancer-specific survival and overall survival. Triple-therapy was associated with better median cancer-specific survival (49 vs 34 months) and overall survival (49 vs 35 months) compared to surgery plus chemotherapy in DSRCT patients.
Synapse has enriched 10 related papers. Consider them for comparative context: